-ichi Inui UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients signifi cant association was found between severe neutropenia and other UGT1A1 polymorphisms or SLCO1B1 polymorphisms. Conclusion. These fi ndings suggest that the UGT1A1*6 polymorphism is a potential predictor of severe neutropenia caused by irinotecan in Japanese cancer patients.
Introduction
Irinotecan, an anticancer agent that inhibits topoisomerase I, is widely used in the treatment of colorectal, gastric, and lung cancers. 1, 2 However, adverse drug reactions such as severe diarrhea and neutropenia limit the dose of this drug. Irinotecan is metabolized by carboxylesterase to form an active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), which, in turn, is subsequently conjugated by UGTglucuronosyltransferase 1A1 (UGT1A1) to yield an inactive form, SN-38 glucuronide (SN-38G). It has been demonstrated that genetic variants of UGT1A1 such as UGT1A1*28 are associated with the occurrence of adverse events in irinotecan chemotherapy. [3] [4] [5] [6] The distribution of UGT1A1*28 differs greatly between Caucasians and Japanese; namely, the frequency of UGT1A1*28 is high in Caucasians, whereas it is low in Asians, including Japanese. 7, 8 On the other hand, UGT1A1*6, a nonsynonymous single nucleotide polymorphism (SNP) in exon 1, was frequently found in an Asian population. 9 In early analyses of Japanese cancer patients, UGT1A1*6 alone could not be proven to be either associated with severe irinotecan-related toxicity, 5 or to decrease the area under the concentration curve ratio of SN-38G to SN-38. 10 However, the presence of UGT1A1*6 together with another polymorphism such as UGT1A1*28 or UGT1A1*60 did alter the disposition of irinotecan. [10] [11] [12] Recently, Han et al. 13 reported that homozygosity for UGT1A1*6 was associated with grade 4 neutropenia in Koreans. Thus, the impact of Abstract Background. Gene polymorphisms of the UDP-glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) contribute to individual variations in adverse events among patients administered irinotecan, and the distribution of the polymorphisms shows large interethnic differences. Variation in the solute carrier organic anion-transporter family, member 1B1 (SLCO1B1) gene also has a signifi cant effect on the disposition of irinotecan in Asian cancer patients. In the present study, we evaluated the association of genetic polymorphisms of UGT1A1 and SLCO1B1 with irinotecanrelated neutropenia in Japanese cancer patients. UGT1A1*6 alone on the toxicity of irinotecan is not well understood in Asians, especially in Japanese. In addition to UGT1A1, genetic variation in the carboxylesterase 1 (CES1) gene, 14 the multidrug resistance-associated protein 2 (MRP2) gene, 15 and the solute carrier organic anion-transporter family, member 1B1 (OATP1B1; SLCO1B1) gene, 16, 17 is suggested to be associated with interindividual variability in the pharmacokinetics and/or toxicity of irinotecan. OATP1B1, which mediates the hepatic uptake of SN-38, was reported to have a signifi cant effect on the disposition of irinotecan in Asian cancer patients. 17 Xiang et al. 17 demonstrated that patients with the SLCO1B1*15 haplotype, which comprised both the *1b and *5 alleles, had an altered disposition of irinotecan characterized by a low rate of clearance of irinotecan and a high plasma level of SN-38. These fi ndings suggested that a combination of polymorphisms for UGT1A1 and SLCO1B1 may be associated with the variation in the toxicity of irinotecan. In the present study, we evaluated the relationship between severe neutropenia caused by irinotecan and genetic variations of UGT1A1 (*60, *28, *6, and *27) and SLCO1B1 (*1b, *5, and haplotype *15) in Japanese cancer patients.
Patients and methods

Patients
From March 2006, Japanese cancer patients treated with irinotecan at the Outpatient Oncology Unit, Kyoto University Hospital, were consecutively enrolled in this study. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events 3.0, and was prospectively recorded by using an electric medical record-based database system (CyberOncology, Cyber Laboratory, Tokyo, Japan). Severe neutropenia referred to events observed during the fi rst cycle of irinotecan treatment. This study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the Ethics Committee (G-192) of Kyoto University Graduate School and Faculty of Medicine. Written informed consent was obtained from all patients.
Genotyping
Genomic DNA was extracted from whole blood by use of the Wizard Genomic DNA Purifi cation Kit (Promega, Madison, OH, USA).
Polymerase chain reaction (PCR) was performed using the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA) with rTaq (Takara Bio, Shiga, Japan). The specifi c primers used in this study are listed in Table 1 . The PCR conditions were 94°C for 3 min, followed by 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 40 s, and then a fi nal extension at 72°C for 7 min. The products were separated on a 1% agarose gel and purifi ed using the Wizard SV Gel and PCR Clean-Up System (Promega). The purifi ed PCR products were then sequenced with a multicapillary DNA sequencer RISA384 System (Shimadzu, Kyoto, Japan). UGT1A1 variants (−3297G>T: UGT1A1*60, promoter TA indel: UGT1A1*28, 211G>A: UGT1A1*6, 686C>A: UGT1A1*27) and SLCO1B1 variants (388A>G: SLCO1B*1b, 521T>C: SLCO1B*5, containing both 388A>G and 521T>C: SLCO1B*15) were genotyped.
Statistics
We hypothesized that the frequency of patients harboring UGT1A1*28 gene polymorphisms (+/− or +/+) would be 20%, and that incidences of expected severe (grade 3 or 4) neutropenia for patients with any polymorphisms and those without polymorphisms would be 50% and 20%, respectively (odds ratio [OR], 4.0). When a χ 2 test with a two-sided signifi cance level of 0.05 had 80% power to detect the difference among incidences of adverse events, a total of 132 samples were necessary to evaluate this study.
The associations between severity of neutropenia and patients' characteristics (sex, age, primary disease, previous treatments, and pretreatment clinical laboratory values) or differences in irinotecan treatment (chemotherapy regimens, the intended schedule, and dosage for each infusion of irinotecan) were assessed with Fisher's exact test or Wilcoxon's rank sum test. Statistical analyses for the association between the severity of neutropenia and UGT1A1 or SLCO1B1 genotypes were performed with Fisher's exact test. To estimate the crude or adjusted OR with a 95% confi dence interval (CI), a logistic regression analysis was conducted. The association between SLCO1B1 and UGT1A1*6 was assessed using Fisher's exact test. Statistical analyses were carried out with SPSS for windows, version 11.0 (SPSS Japan, Tokyo, Japan). A two-tailed P value of less than 0.05 was considered statistically signifi cant.
Results
Patients
From March 2006 to December 2006, 135 patients were enrolled in this study. Among them, 133 were evaluated. Two patients were excluded, 1 because the planned fi rst course could not be completed and the other because the clinical laboratory data were incomplete. The patients' characteristics are listed in Table 2 . During the fi rst course, 29 (22%) patients experienced severe neutropenia. A signifi cant association was observed between the pretreatment level of neutrophils and the total level of bilirubin. No signifi cant differences were found among patients with severe neutropenia and those without according to information on irinotecan chemotherapy.
UGT1A1 and SLCO1B1 genotypes and allele frequency
The UGT1A1 and SLCO1B1 allele frequencies in this study are listed in Table 3 . The numbers of individuals homozygous for UGT1A1*60, UGT1A1*6, and SLCO1B1*1b were 7 (5.3%), 6 (4.5%), and 67 (50.0%), respectively. Only 1 patient was homozygous for UGT1A1*28. No patient had UGT1A1*27 and none were homozygous for SLCO1B1*5 or SLCO1B1*15. The frequencies of the UGT1A1 and SLCO1B1 genotypes were similar to those previously reported in Asian subjects. [8] [9] [10] [11] 13 Association of UGT1A1 or SLCO1B1 genotypes with severe irinotecan-related neutropenia With respect to UGT1A1, a signifi cant association was observed between the UGT1A1*6 allele and severe neutropenia (+/ Table 4 ). The grade of neutropenia in the 6 patients with UGT1A1*6(+/+) was grade 3 in 3 patients, grade 2 in 1 patient, and grade 1 in 2 patients. The incidence of neutropenia was higher with the +/+ or +/− alleles for UGT1A1*6 than with the −/− alleles. Meanwhile, no signifi cant association was found between other UGT1A1 polymorphisms, including UGT1A1*28, SLCO1B1*1b, SLCO1B1*5, and SLCO1B1*15, and severe neutropenia.
After adjustments were made for the potential confounding variables listed in Table 2 , the importance of UGT1A1*6 was verifi ed (+/+, adjusted OR, 7.63; 95% CI, 1.05-55.61; P = 0.045; +/−, adjusted OR, 5.19; 95% CI, 1.80-14.98; P = 0.002; Table 5 ). There was no signifi cant association between other genotypes and severe neutropenia (data not shown).
Infl uence of SLCO1B1*15 on neutropenia in patients with UGT1A1*6
To evaluate the synergistic effect of SLCO1B1*15 on UGT1A1*6, patients with the UGT1A1*6 allele were divided into two groups; those with and those without SLCO1B1*15. There was no signifi cant effect of SLCO1B1*15 on neutropenia regardless of UGT1A1*6 status (Table 6 ).
Discussion
In the present study, we demonstrated that severe neutropenia was highly correlated with UGT1A1*6 in a multiple logistic regression analysis. This fi nding apparently does not agree with previous reports that UGT1A1*6 alone was not associated with severe toxicity, 5 and that the glucuronidation of SN-38 was not signifi cantly affected in patients with UGT1A1*6 alone. 10, 12 The reasons for these discrepancies are not clear, but several studies have shown the importance of UGT1A1*6 in Asian populations. First, Han et al. 13 reported that only homozygosity for UGT1A1*6 was associated with a higher incidence of grade 4 neutropenia (P = 0.044) in a Korean population. While we were preparing this manuscript, Minami et al. 11 also pointed out the importance of UGT1A1*6 in combination with UGT1A1*28 for predicting irinotecan-related neutropenia. Second, the neonatal hyperbilirubinemia found in Japanese is signifi cantly associated with UGT1A1*6, but not with UGT1A1*28, 18, 19 whereas that occurring in Caucasians is related to UGT1A1*28. 20 Third, as UGT1A1*6 is genetically linked with gene polymorphisms of UGT1A7 and UGT1A9, the proteins of which also participate in the glucuronidation of SN-38 in vitro 21, 22 and in vivo, 23 the enzyme activities of other UGTs might be affected by UGT1A1*6. Based on these fi ndings, it is very reasonable to conclude that UGT1A1*6 is a signifi cant genetic marker for predicting irinotecan-related toxicity in Japanese cancer patients. UGT1A1*28 was not signifi cantly associated with irinotecan-related toxicity in our study, although the signifi cance of this variant had been confi rmed in several studies, especially in Caucasians. 3, 4, 6 For setting the number of patients for the present analyses, the frequency of patients harboring UGT1A1*28 gene polymorphisms (+/− and +/+) was assumed to be 20%, and the actual frequency of patients harboring UGT1A1*28 (+/− and +/+) was calculated as 17%. Thus, the absence of a signifi cant correlation between UGT1A1*28 and severe neutropenia was not due to a lack of power for detection. One possible explanation is the interethnic differences in allele frequency for UGT1A1*28, which is several times higher in Caucasians (0.29-0.389) 4, 7, 9 than in Asians (0.07-0.138). [8] [9] [10] [11] 13 Actually, there was only one patient with UGT1A1*28 (+/+) in the present analysis. As another factor, the dosage of irinotecan may be taken into consideration. In our analysis, most of the irinotecan doses administered were low (<150 mg/m 2 ). Recently, Hoskins et al. 24 reported the association between irinotecan dose and the risk of hematologic toxicity among patients with a UGT1A1*28/*28 genotype, and indicated that a low dose of irinotecan would not affect the incidence of hematologic toxicity. One of the reasons for the lack of support for a signifi cant association of UGT1A1*28 with irinotecaninduced toxicity in our study may be the small number of patients having UGT1A1*28 (+/+) and the low doses of irinotecan administered. Further studies with limited conditions may be needed to assess the functional importance of UGT1A1*28.
Recently, Minami et al. 11 reported that homozygosity and double heterozygosity for UGT1A1*6 and*28 (*6/*6, *28/*28, and *6/*28) were signifi cantly associated with severe neutropenia in a multivariate analysis in Japanese cancer patients. The signifi cance of double heterozygosity (*6/*28) in Japanese was also reported in terms of the pharmacokinetic profi le of SN-38. 12 Based on these fi ndings, Minami et al. 11 concluded that the genotyping of UGT1A1*6 and*28 would be benefi cial and necessary in Japanese cancer patients to avoid severe adverse reactions. However, double heterozygosity (*6/*28) could be detected as UGT1A1*6 (+/−) by the genotyping of UGT1A1*6, and the frequency of homozygosity for UGT1A1*28 was rare (0.75% in the present analysis). Taken together, the above fi ndings and our results seem to indicate that the genotyping of UGT1A1*6 may be more clinically important than that of It has been reported that genetic polymorphisms of SLCO1B1 infl uence the hepatic disposition of various drugs, including the HMG-CoA reductase inhibitor pravastatin. 25, 26 Interestingly, SLCO1B1 has also been related to the altered pharmacokinetics of irinotecan and its metabolites. 17 In the present study, we found no effect of SLCO1B1 and no synergistic effect for UGT1A1*6. The transport of SN-38 was stimulated 1.6 fold in OATP1B1-expressing cells compared to mock cells, 16 and this stimulation was markedly lower than that shown by a typical substrate, pravastatin (40-fold). 26 It is, therefore, suggested that the contribution of SLCO1B1 to irinotecan-related neutropenia was weak in comparison with that of UGT1A1.
In conclusion, we demonstrated that severe neutropenia was highly correlated with UGT1A1*6. Considering its high allele frequencies, genotyping for UGT1A1*6 may be useful to predict the risk of irinotecan-related neutropenia in Japanese patients.
